Medications

Retatrutide: The Triple Agonist GLP-1 Drug That May Outperform Ozempic and Mounjaro

GLP-1 Companion · 8 min read

Retatrutide (also known by its development name LY3437943) is an investigational weight loss drug developed by Eli Lilly that is generating significant scientific and public interest. Unlike current GLP-1 medications that act on one or two receptor pathways, retatrutide simultaneously activates three: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This makes it a "triple agonist" — a category that does not yet have an approved drug on the market.

What Receptors Does Retatrutide Target?

To understand what makes retatrutide different, it helps to compare it to existing drugs.

• Semaglutide (Ozempic, Wegovy): Acts on GLP-1 receptors only. A single agonist.
• Tirzepatide (Mounjaro, Zepbound): Acts on both GLP-1 and GIP receptors. A dual agonist.
• Retatrutide: Acts on GLP-1, GIP, and glucagon receptors. A triple agonist.

Adding glucagon receptor activation is the key distinction. Glucagon is a hormone that raises blood sugar, increases metabolic rate, and promotes the burning of fat stored in the liver. When activated in combination with GLP-1 and GIP signaling, the glucagon component may amplify energy expenditure — in other words, it may help the body burn more calories, not just consume fewer.

What Do the Clinical Trials Show?

Phase 2 clinical trial results for retatrutide, published in 2023 in the New England Journal of Medicine, showed remarkable weight loss outcomes. Participants taking the highest dose (12 mg weekly) lost approximately 24.2% of their body weight over 48 weeks. For context:

• Semaglutide (Wegovy) produces approximately 15% weight loss over 68 weeks in phase 3 trials.
• Tirzepatide (Zepbound) produces approximately 20-22% weight loss over 72 weeks in phase 3 trials.
• Retatrutide at 12mg produced ~24% weight loss in just 48 weeks in phase 2.

It is important to note that phase 2 trials are smaller and not directly comparable to phase 3 results. Phase 3 trials enroll more participants, run longer, and are more rigorously controlled. Retatrutide's phase 3 trials (known as TRIUMPH) are currently underway, and results are expected in 2026.

Why Is Retatrutide Generating So Much Interest?

Several factors are driving intense attention toward retatrutide:

1. Potentially Superior Weight Loss

The 24% average weight loss seen in the highest-dose group of the phase 2 trial exceeded what any approved GLP-1 medication has achieved in equivalent timeframes. Some participants lost more than 30% of their body weight, approaching the outcomes typically seen with bariatric surgery.

2. Liver Fat Reduction

The glucagon receptor activation appears to drive significant reductions in liver fat. This is particularly important for patients with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease. Some participants in trials experienced dramatic reductions in liver fat, a clinically meaningful outcome beyond weight alone.

3. Metabolic Rate Preservation

A persistent concern with all weight loss medications is that significant caloric restriction can slow metabolic rate and cause muscle loss. The glucagon component of retatrutide may help counteract this by increasing energy expenditure, potentially preserving or even improving metabolic rate during weight loss.

What Are the Side Effects of Retatrutide?

The side effect profile reported in phase 2 trials was broadly similar to other GLP-1 medications, with gastrointestinal symptoms being the most common:

• Nausea: Most common side effect, particularly at the start of treatment and during dose escalation.
• Vomiting: Reported less frequently than nausea, typically subsiding after adjustment.
• Diarrhea and constipation: Both occurred in trial participants, consistent with GLP-1 class effects.
• Decreased appetite: Considered a primary mechanism of action rather than an adverse effect.
• Injection-site reactions: Mild redness or swelling at injection sites, similar to other injectables.

One area of attention with retatrutide is the potential for more pronounced effects on heart rate, given glucagon's cardiovascular actions. The phase 3 trials are specifically designed to assess cardiovascular safety at length. No significant safety concerns have emerged in phase 2 data published to date.

How Is Retatrutide Administered?

Like semaglutide and tirzepatide, retatrutide in clinical trials is administered as a weekly subcutaneous (under the skin) injection. The dosing regimen used in trials started low and gradually escalated — a standard approach with GLP-1 class medications to minimize GI side effects while the body adjusts.

When Might Retatrutide Be Available?

Retatrutide is currently in phase 3 clinical trials (the TRIUMPH program), which is the final stage before a company can submit for FDA approval. If phase 3 results are strong and the FDA review proceeds efficiently, retatrutide could potentially seek approval in 2026 or 2027. However, drug development timelines are inherently uncertain, and no approval is guaranteed.

Eli Lilly has not announced pricing or access plans for retatrutide, as it remains an investigational drug. Coverage decisions will depend heavily on the final label, clinical outcomes, and negotiations with payers once the drug is approved.

How Does Retatrutide Compare to Tirzepatide (Mounjaro/Zepbound)?

Tirzepatide, Eli Lilly's current approved dual agonist, already outperforms semaglutide in head-to-head comparisons. Retatrutide adds glucagon receptor activation on top of tirzepatide's GLP-1/GIP mechanism. The key question from phase 3 trials will be whether adding the glucagon pathway translates to meaningfully better outcomes in larger, longer studies — and whether the side effect profile remains manageable.

What Should You Do If You Are Interested in Retatrutide?

Retatrutide is not yet available outside of clinical trials. If you are interested in participating in a trial, you can search for open TRIUMPH trial sites at ClinicalTrials.gov using the search term "retatrutide." Eligibility criteria typically include a BMI of 30 or higher (or 27 or higher with a weight-related health condition).

If you are seeking the most effective currently approved GLP-1 treatment, tirzepatide (Zepbound for weight loss, Mounjaro for type 2 diabetes) represents the current standard, with strong efficacy data and FDA approval. Talk to your healthcare provider about which approved option may be right for you while the field continues to evolve.

The emergence of triple agonists like retatrutide signals a rapidly advancing field. For patients who have not responded adequately to current medications, the next generation of treatments may offer additional options — but medical supervision remains essential regardless of which therapy you pursue.

Sources

• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023.
• ClinicalTrials.gov — TRIUMPH Phase 3 Program for Retatrutide.